Effect of beta-agonists on expression of calpain and calpastatin activity in skeletal muscle.
Administration of beta-adrenergic agonists to domestic species can lead to skeletal muscle hypertrophy, probably by reducing the rate of myofibrillar protein breakdown. Myofibrillar breakdown is associated with the calcium-dependent proteinase system (calpains I,II and calpastatin) whose activity also changes during beta-agonist treatment. A number of growth trials using the agonists cimaterol and clenbuterol with cattle, sheep, chicken and rat are reported which suggest a general mechanism whereby beta-agonists reduce calpain I activity, but increase calpain II and calpastatin activity in skeletal muscle. Parallel changes in specific mRNAs indicate that changes in gene expression or stabilisation of mRNA could in part explain the changes in activity.
Bardsley
R G
RG
Department of Applied Biochemistry and Food Science, University of Nottingham, School of Agriculture, Sutton Bonington, Loughborough, UK.
Allcock
S M
SM
Dawson
J M
JM
Dumelow
N W
NW
Higgins
J A
JA
Lasslett
Y V
YV
Lockley
A K
AK
Parr
T
T
Buttery
P J
PJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002135:Calcium-Binding Proteins / Q000235:genetics*; D002154:Calpain / Q000235:genetics*; D002417:Cattle; D002645:Chickens; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000201:enzymology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012756:Sheep
D000318:Adrenergic beta-Agonists; D002135:Calcium-Binding Proteins; D004983:Ethanolamines; D012333:RNA, Messenger; C033668:calpastatin; D002154:Calpain; C047411:cimaterol